secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kura Oncology, Inc. (KURA)
CIK:        0001422143
Form:       8-K
Filed at:   2022-11-03T23:59:59+00:00
Accession:  0000950170-22-021564
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kura Oncology Q3 net loss $35.5M; $150M financing; ziftomenib data at ASH
-------------------------------------------------------------------------

- Q3 net loss $35.5M vs $33.4M YoY; R&D expense $25.0M, G&A $11.6M.
- Cash, equivalents & short-term investments $427.8M pro forma $462.8M after $25M BMS equity and $10M Hercules draw.
- $125M Hercules term loan: $10M drawn immediately, up to $115M additional upon milestones; runway into 2026.
- Updated ziftomenib Phase 1 data from KOMET-001 accepted for oral presentation at ASH Dec 10, 2022.
- AIM-HN registration trial of tipifarnib in HRAS mutant HNSCC closed to enrollment; KURRENT-LUNG trial initiated.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1422143/000095017022021564/0000950170-22-021564-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1422143/000095017022021564/kura-20221103.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-021564

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer